Oropharyngeal candidiasis: A review of its clinical spectrum and current therapies

Clinical Therapeutics

Volumn 20, Issue 1, 1998, Pages 40-57

  Epstein, Joel B ^a,b,d   Polsky, Bruce ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Amphotericin B oral suspension; Candida albicans; Oral mucosa; Oropharyngeal candidiasis

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CHLORHEXIDINE GLUCONATE; CLOTRIMAZOLE; FLUCONAZOLE; IMIDAZOLE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; POLYENE ANTIBIOTIC AGENT; TRIAZOLE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CANDIDIASIS; CLINICAL EXAMINATION; DRUG CHOICE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTRAVENOUS DRUG ADMINISTRATION; PHARYNGITIS; SUSPENSION; THRUSH; TOPICAL DRUG ADMINISTRATION; TREATMENT INDICATION;

EID: 0031906790     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80033-7     Document Type: Review

References (92)

1. Epstein JB. Antifungal therapy in oropharyngeal mycotic infections. Oral Surg Oral Med Oral Pathol. 1990;69:32-41.
2. Guida RA. Candidiasis of the oropharynx and esophagus. Ear Nose Throat J. 1988; 67:832-840.
3. Dreizen S. Oral candidiasis. Am J Med. 1984;30:28-33.
4. Budtz-Jörgensen E. Etiology, pathogenesis, therapy, and prophylaxis of oral yeast infections. Acta Odontol Scand. 1990;48: 61-69.
5. Greenspan D. Treatment of oropharyngeal candidiasis in HIV-positive patients. J Am Acad Dermatol. 1994;31(Suppl):51-55.
6. Meyer RD, Holmherg K. Fungal infection in HIV-infected patients. In: Homberg K. Meyer R, eds. Diagnosis and Therapy of Systemic Fungal Injections. New York: Raven Press; 1989:79-100.
7. Peterson DE. Oral candidiasis. Clin Geriatr Med. 1992;8:513-527.
8. Dhondt F. Ninane J. De Beule K, et al. Oral candidosis: Treatment with absorbable and non-absorbable antifungal agents in children. Mycoses. 1992;35:1-8.
9. Epstein JB. Oral and pharyngeal candidiasis. Postgrad Med. 1989;85:257-269.
10. Burton DM, Seid AB, Kearns DB, Pransky SM. Candida laryngotracheitis: A complication of combined steroid and antibiotic usage in croup. Int J Pediatr Otorhinolaryngol. 1992;23:171-175.
11. Garber GE. Treatment of oral Candida mucositis infections. Drugs. 1994;47: 734-740.
12. Lundstrom IM, Anneroth GB, Holmberg K. Candida in patients with oral lichen planus. Int J Oral Surg. 1984;13:226-238.
13. Nikawa H, Samaranayake LP, Tenovuo J, Hamada T. The effect of antifungal agents on the in vitro susceptibility of Candida albicans to apo-lactoferrin. Arch Oral Biol. 1994;39:921-923.
14. Spijkervet FK, van Saene HK, van Saene JJM, et al. Mucositis prevention by selective elimination of oral flora in irradiated head and neck cancer patients. J Oral Pathol Med. 1990;19:486-489.
15. Francis P, Walsh TJ. Current approaches to the management of fungal infections in cancer patients. Oncology. 1992;6:81-92.
16. Prentice AG. Oral and gastrointestinal candidosis: Prophylaxis during immunosuppressive therapy. Mycoses. 1989;32 (Suppl 2):42-46.
17. DeGregorio MW, Lee WMF, Ries CA. Candida infections in patients with acute leukemia: Ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer. 1982;50:2780-2784.
18. Stevens DA, Green SI, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Arch Intern Med. 1991; 151:2458-2464.
19. Epstein JB, Ransier A, Lunn R, et al. Prophylaxis of candidiasis in patients with leukemia and bone marrow transplants. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;81:291-296.
20. Epstein JB, Vickars L, Spinelli J, Reece D. Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surg Oral Med Oral Pathol. 1991;73:682-689.
21. Epstein JB, Frelich MM, Le ND. Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol. 1993; 76:169-174.
22. Bergmann OJ. Alterations in oral microflora and pathogenesis of acute oral infections during remission-induction therapy in patients with acute myeloid leukaemia. Scand J Infect Dis. 1991;23: 355-366.
23. Bergmann OJ, Andersen PL. Acute oral candidiasis during febrile episodes in immunocompromised patients with haematologic malignancies. Scand J Infect Dis. 1990;22:353-358.
24. Rodu B, Carpenter JT, Jones MR. The pathogenesis and clinical significance of cytologically detectable oral Candida in acute leukemia. Cancer. 1988;62:2042-2046.
25. Morrison VA, Pomeroy C. Upper respiratory tract infections in the immunocompromised host. Semin Respir Infect. 1995; 10:37-50.
26. Dupont B, Graybill JR, Armstrong D, et al. Fungal infections in AIDS patients. J Med Vet Mycol. 1992;30(Suppl 1):19-28.
27. Koks CHW, Schepens MHJ, Burger DM, et al. Drug development report (9): Fluconazole in the treatment and prophylaxis of oral candidosis in HIV-infected patients. J Drug Dev Clin Pract. 1993;5: 235-249.
28. Heinic GS, Stevens DA, Greenspan D. Fluconazole-resistant Candida in AIDS patients. Oral Surg Oral Med Oral Pathol. 1993;76:711-715.
29. Pollock JJ, Santarpia RP III, Heller HM, et al. Determination of salivary anticandidal activities in healthy adults and patients with AIDS: A pilot study. J Acquired Immune Defic Syndr Hum Retrovirol. 1992; 5:610-618.
30. Conant MA. The AIDS epidemic. J Am Acad Dermatol. 1994;31:S47-S50.
31. Jewell ME, Sweet DE. Oral and dermatologie manifestations of HIV infection. Postgrad Med. 1994;96:105-116.
32. Crislip MA, Edwards JE. Candidiasis. Infect Dis Clin North Am. 1989;3:103-133.
33. Edwards JE. Candida species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practices of Infectious Diseases. New York: Churchill Livingstone; 1995:2289-2301.
34. Lewis MAO, Samaranyake LP, Lamey PJ. Diagnosis and treatment of oral candidiasis. J Oral Maxillofac Surg. 1991;49: 996-1002.
35. Bissell V, Felix DH, Wray D. Comparative trial of fluconazole and amphotericin in the treatment of denture stomatitis. Oral Surg Oral Med Oral Pathol. 1993;76: 35-39.
36. Berkow R, ed. The Merck Manual of Diagnosis and Therapy. 16th ed. Rahway, NJ: Merck & Co. Inc.; 1992.
37. Epstein JB, Truelove EL, Izutzu KT. Oral candidiasis: Pathogenesis and host defense. Rev Infect Dis. 1984;6:96-106.
38. Epstein JB, Pearsall NN, Truelove EL. Quantitative relationships between Candida albicans in saliva and the clinical status of human subjects. J Clin Microbiol. 1980;12:475-476.
39. Rex JH, Cooper CR, Merz WG, et al. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother. 1995;39: 906-909.
40. Barchiesi F, Del Poeta M, Morbiducci V, et al. Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans. Mycopathologia. 1993;124:19-250.
41. Woods GL, Washington JA. The clinical and the microbiology laboratory. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practices of Infectious Diseases. New York: Churchill Livingstone; 1995:169-199.
42. Galgiani JN. Antifungal susceptibility tests. Antimicrob Agents Chemother. 1987; 31:1867-1870.
43. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990;12:308-329.
44. Korting HC, Ollert M, Georgii A, Fröschl M. In vitro susceptibilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus. J Clin Microbiol. 1988;26:2626-2631.
45. Gupta AK, Sauder DN, Shear NH. Antifungal agents: An overview. Part 1. J Am Acad Dermatol. 1994;30:677-698.
46. Judd G. Oral candidiasis - Treatment choices. On Contin Pract. 1989;16:21-22.
47. Datry A. Candidose digestive et infection vih. Actualités cliniques et thérapeutiques. J Mycol Med. 1992;2(Suppl I):5-14.
48. Samaranayake LP, Ferguson MM. Delivery of antifungal agents to the oral cavity. Adv Drug Deliv Rev. 1994;13:161-179.
49. Dewsnup DH, Stevens DA. Efficacy of oral amphotericin B in AIDS patients with thrush clinically resistant to fluconazole. J Med Vet Mycol. 1994;32:389-393.
50. Bennett JE. Antimicrobial agents, antifungal agents. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon Press; 1990:1165-1181.
51. Barkvoll P, Attramadal A. Effect of nystatin and chlorhexidine digluconate on Candida albicans. Oral Surg Oral Med Oral Pathol. 1989;67:279-281.
52. Barkvoll P, Hurlen B. Conventional treatment of oral candidiasis - New aspects. Nor Tannlaegeforen Tid. 1989;99:116-119.
53. Philpott-Howard JN, Wade JJ, Mufti GJ, et al. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. J Antimicrob Chemother. 1993;31:973-984.
54. Egger T, Gratwohl A, Tichelli A, et al. Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center study. Supportive Care Cancer. 1995;3:139-146.
55. Donnelly JP, Starke ID, Galton DAG, et al. Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia. J Hosp Infect. 1984;5:83-91.
56. Menichetti F, Del Favero A, Martino P, et al. Preventing fungal infection in neutropenic patients with acute leukemia: Fluconazole compared with oral amphotericin B. Ann Intern Med. 1994;120:913-918.
57. Owens NJ, Nightingale CH, Schweizer RT, et al. Prophylaxis of oral candidiasis with clotrimazole troches. Arch Intern Med. 1984;144:290-293.
58. Shechtman LB, Funaro L, Robin T, et al. Clotrimazole treatment of oral candidiasis in patients with neoplastic disease. Am J Med. 1984;76:91-94.
59. Goldstein SM. Advances in the treatment of superficial Candida infections. Semin Dermatol. 1993;12:315-330.
60. Uchida K, Yamaguchi H. Susceptibility to miconazole (base) of isolates from the oral cavity and esophagus of patients with mycosis. Jpn J Antibiot. 1991;44:109-116.
61. Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis. 1992; 165:891-897.
62. Gupta KL, Ghosh AK, Kochhar R, et al. Esophageal candidiasis after renal transplantation: Comparative study in patients on different immunosuppressive protocols. Am J Gastroenterol. 1994;89:1062-1065.
63. van der Bijl P, Arendorf TM. Itraconazole and fluconazole in oropharyngeal candidiasis. Ann Dent. 1993;52:12-16.
64. Meunier F. Fluconazole treatment of fungal infections in the immunocompromised host. Semin Oncol. 1990;17(Suppl 6):19-23.
65. Hansen RM, Reinerio N, Sohnle PG, et al. Ketoconazole in the prevention of candidiasis in patients with cancer. A prospective, randomized, controlled, double-blind study. Arch Intern Med. 1987;147:710-712.
66. Hay RJ. Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Infect Dis. 1990;12(Suppl 3):334-337.
67. Conly A, Renin R, Johnson J, et al. Disseminated candidosis due to amphotericin B resistant Candida albicans. J Infect Dis. 1992,165:761-764.
68. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 1995;39: 1-8.
69. White A, Goetz MB. Azole-resistant Candida albicans: Report of two cases of resistance to fluconazole and review. Clin Infect Dis. 1994;19:687-692.
70. Ng TTC, Denning DW. Fluconazole resistance in Candida in patients with AIDS - A therapeutic approach. J Infect. 1993;26:117-125.
71. Newman SL, Flanigan TP, Fisher A, et al. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis. 1994;19: 684-686.
72. Chavanet P, Lopez J, Grappin M, et al. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS. 1994;8:945-950.
73. Samaranayake LP, Holmstrup P. Oral candidiasis and human immunodeficiency virus infection. J Oral Pathol Med. 1989: 18:554-564.
74. Manso E, Montillo M, Discepoli G, Leoni P. Fluconazole resistance of Candida krusei. Boll 1st Sieroter Milan. 1991;70: 527-529.
75. Redding S, Smith J, Farinacci G. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: Documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis. 1994;18:240-242.
76. Laguna F, Rodriguez-Tudela JL, Enriquez A. Fungemia due to fluconazole-resistant Candida albicans in a patient with AIDS. Clin Infect Dis. 1994;19:542-543.
77. Lucatorto FM, Franker C, Hardy WD, Chafey S. Treatment of refractory oral candidiasis with fluconazole. A case report. Oral Surg Oral Med Oral Pathol. 1991;71:42-44.
78. Fan-Havard P, Capano D, Smith SM, et al. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother. 1991;35:2302-2305.
79. Akova M, Akalin HE, Uzun O, Gur D. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur J Clin Microbiol Infect Dis. 1991;10:598-599.
80. Leibovitz E, Rigaud M, Chandwani S, et al. Disseminated fungal infections in children infected with human immunodeficiency virus. Pediatr Infect Dis J. 1991; 10:888-894.
81. Axéll T, Budtz-Jörgensen E, Oksala E, et al. Few aspects with regard to diagnosis and treatment of oral candidiasis. Nor Tannlaegeforen Tid. 1989;99:156-160.
82. de Vries-Hospers HG, Mulder NH, Sleijfer DT, van Saene HK. The effect of amphotericin B lozenges on the presence and number of Candida cells in the oropharynx of neutropenic leukemia patients. Infection. 1982;10:71-75.
83. de Vries-Hospers HG, van der Waaij D. Salivary concentrations of amphotericin B following its use as an oral lozenge. Infection. 1980;8:63-65.
84. Terrell CL, Hermans PE. Antifungal agents used for deep-seated mycotic infections. Mayo Clin Proc. 1987;62:1116-1128.
85. Bradley SG, Farber PJ, Jones LA. Action of polyene antibiotics on Candida. Antimicrob Agents Annu. 1960;558-569.
86. Ghosh A, Ghosh JJ. Effect of nystatin and amphotericin B on the growth of Candida albicans. Ann Biochem Exptl Med. 1963; 23:29-44.
87. Lechevalier H. Comparison of the in vitro activity of four polyenic antifungal antibiotics. Antihiot Annu. 1959-1960;614-618.
88. Alban J, Groel JT. Amphotericin B oral suspension in the treatment of thrush. Curr Ther Res. 1970;12:479-484.
89. Montes LF. Oral amphotericin B in superficial candidiasis. Clin Med. 1971:14-17.
90. Brandell R, Chase SL, Cohn JR. Treatment of oral candidiasis with amphotericin B solution. Clin Pharm. 1988;7:70-72.
91. Stough AR, Groel JT, Kroeger WH. Amphotericin B, a new antifungal agent for the prophylaxis of antibiotic-induced moniliasis. Antibiot Med Clin Ther. 1959; 6:653-661.
92. Louria DB. Some aspects of the absorption, distribution, and excretion of amphotericin B in man. Antibiot Med Clin Ther. 1958;5:295-301.